Metformin Genericon

Metformin, the active ingredient in Metformin Genericon, is a biguanide presented as a tablet for oral use. It lowers blood glucose levels and is used to treat type 2 diabetes mellitus in adult patients. The drug improves insulin sensitivity in peripheral tissues and reduces hepatic glucose production, supporting overall glycemic control.\n\nGNH India supplies Metformin Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides batch‑tested products with full regulatory documentation for global distribution.

Metformin, a biguanide antidiabetic agent, is employed primarily in the management of type 2 diabetes mellitus, a chronic condition characterized by insulin resistance and elevated hepatic glucose production.\n\nType 2 diabetes mellitus: improves glycemic control by decreasing hepatic glucose output and enhancing peripheral insulin sensitivity, leading to lower fasting and post‑prandial blood glucose levels.\nPrediabetes (impaired fasting glucose): may delay progression to type 2 diabetes when used together with lifestyle modification.

Metformin may cause a range of adverse reactions, most of which are mild and transient.\n\nCommon Side Effects:\n- Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia.\n- Diarrhea: loose stools occurring especially after dose initiation.\n- Metallic taste: transient alteration of taste perception.\n- Loss of appetite: reduced desire to eat.\n- Flatulence: increased intestinal gas.\n- Weight loss: modest reduction in body weight.\n\nSerious or Rare Side Effects:\n- Lactic acidosis: a rare but life‑threatening accumulation of lactate.\n- Vitamin B12 deficiency: may develop with long‑term therapy.\n- Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Hepatic dysfunction: abnormal liver enzymes or hepatitis.\n- Hypoglycemia: when combined with insulin or other glucose‑lowering agents.\n- Pancreatitis: inflammation of the pancreas.

Metformin requires careful patient assessment and monitoring to minimize risks.\n- Renal function assessment: evaluate creatinine clearance before initiating therapy and periodically thereafter.\n- Lactic acidosis risk: avoid in patients with severe renal impairment, hepatic disease, or conditions predisposing to hypoxia.\n- Alcohol consumption: limit intake as it may increase risk of lactic acidosis.\n- Monitoring: check blood glucose and HbA1c regularly to assess efficacy.\n- Pregnancy and lactation: use only if benefits outweigh risks and under medical supervision.\n- Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metformin can interact with several medicines, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after imaging.\n- Cimetidine: can increase metformin plasma concentrations, raising risk of lactic acidosis.\n- Renal toxic drugs (e.g., aminoglycosides, NSAIDs): may impair renal clearance of metformin.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blockers: may mask symptoms of hypoglycemia.\n- Thiazide diuretics: can enhance hyperglycemic effect.\n- Alcohol: excessive intake can increase lactic acidosis risk.